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Pancreatic carcinoma is a malignancy with a poor prognosis and the 4th. most common cause of cancer-
related deaths. Patients are usually diagnosed at advanced stage of the disease. Surgical resection re-
mains the only potentially curative therapy, as only 20% of the patients present with disease are
amenable to resection. Surgery, chemotherapy, radiotherapy and palliative therapies are therapeutic
options. Multidisciplinary approach is needed for every stage of the disease. Researches showed an
improved survival beneﬁt of radiotherapy (RT) and chemotherapy (CT) combination for locally advanced
unresectable pancreatic carcinoma compared to RT or CT alone. In an attempt to improve survival, the
efﬁcacy of chemoradiation (CRT) after surgery compared to observation has been tested in several trials.
Neoadjuvant CRT achieves a higher probability of margin negative R0 resection. Currently, both 5-FU and
gemcitabine have been used concurrently with RT, and also targeted agents (erlotinib, cetuximab,
panitumumab, bevacizumab) have been also evaluated.
Copyright © 2016 Turkish Society of Medical Oncology. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pancreatic carcinoma is a malignancy with poor prognosis, and
the 4th. most common cause of cancer-related deaths. The Amer-
ican Cancer Society estimated 53.070 new cases of pancreatic
cancer and 41.780 pancreatic cancer erelated deaths in the United
States for the year 2015.1 More than 200.000 deaths around the
world are related to pancreatic carcinoma.2 Most cases occur in
patients between 60 and 80 years of age and rarely before the 4th
decade.3 Male versus female ratio is 1.3:1 and it is most common in
black race.4 Five-year overall survival rates of pancreatic cancer
patients decreased 6% in USA. Most patients present with advanced
disease. Surgery offers the only means of cure, and unfortunately
after diagnosis only 20% of the patients present with tumors
amenable to resection.5 The 5 year-overall survival rates for pa-
tients undergoing pancreatic resection is 25e30% for node negative
and 10% for node positive disease.4 Five-year survival rate of the
patients presenting with metastatic disease is only 5%.6
Ductal adenocarcinomas are the most common histopatholog-
ical type, accounting nearly 95% of all malignant tumors.7 Risk
factors of pancreatic carcinoma include cigarette smoking, alcohol.
ty of Medical Oncology.
ical Oncology. Production and hosconsumption, chronic pancreatitis, obesity, diabetes mellitus, cho-
lecystectomy, gastrectomy and helicobacter pylori infection.8 Ten
percent of this malignancy may be familial. The risk of cancer is
greater among patients with a positive family history.9
Surgery, chemotherapy, radiotherapy and palliative therapies are
therapeutic options. Multidisciplinary approach is needed for every
stage of the disease (Fig. 1). Randomised trials have shown an
improved survival beneﬁt of the radiotherapy (RT) and chemo-
therapy (CT) combination for locally advanced unresectable
pancreatic carcinoma compared to RT or CT alone.10 This review
presents thechemoradiation studies related topancreatic carcinoma.
2. Adjuvant chemoradiotherapy
Early recurrences and low survival rates after pan-
creaticoduodenectomy in 10%e20% of pancreatic carcinoma patients
with localized disease, indicate the need for adjuvant interventions.
Grifﬁn et al analyzed the patterns of treatment failure in 36
patients after curative resection for pancreatic carcinoma. Two and
5-year survival rates among these patients were 32 and 17%,
respectively. The median survival time was 11,5 months. In all pa-
tients treatment failure is associated with presence of metastases
intraabdominal (100%), and peritoneal (42%) cavities, and liver
leading to hepatic failure (62%).11
Willet and colleagues, analyzed patterns of failure after
pancreaticoduodenectomy performed for periampullary carcinomating by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
Fig. 1. The treatment of pancreatic cancer (PC: pancreatic cancer, CT: chemotherapy, CRT: chemoradiation)3
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or T2 stage compared with 44% for T3 or T4 stages. Patients with
lymph node positivity, and negativity had local control rates of 47,
and 87%, respectively moderately differentiated tumors had a bet-
ter local control rate as compared with patients with poorly
differentiated tumors (5-year local control rate 81% vs 0%).12
For the patients undergoing a potentially curative pan-
creatoduodenectomy, 3 major sites of disease relapse dominate:
 the bed of resected pancreas,
 the peritoneal cavity and
 the liver.
Therefore, tumor stage, grade and resection margin status are
the predictors of survival after surgery.
A randomized trial conducted by the Gastrointestinal Tumor
Study Group (GISTG) showed improved overall survival with the
use of adjuvant CRT followed by adjuvant CTafter deﬁnitive surgery
(40 Gy split course RT concomitantly with iv bolus 5-FU 500 mg/m2
on the ﬁrst 3 days and then weekly for 2 years after RT). Patients
who had undergone surgery alone had a median survival of 11
months versus 20 months in the treatment group (p ¼ 0.03). Two-
year overall survival was 42% with chemoradiotherapy arm versus
15% with surgery alone.13
The European Organization for Research and Treatment of
Cancer (EORTC) designed a randomized trial to compare surgery
alone or surgery plus postoperative chemoradiotherapy. Contrary
to GISTG trial, 5-FU was not given after chemoradiotherapy. In the
chemoradiation arm the median survival time was 17 months
versus 13 months in the surgery alone arm. Although no statisti-
cally signiﬁcant difference was observed between two arms, the
trial has been criticized for its lack of any mention of the surgical
margin positivity, lack of quality assurance, inclusion of pancreatic
and periampullary carcinomas, and insufﬁcient statistical power for
subanalysis.14,15
Another important trial is the European Study Group of
Pancreatic Cancer (ESPAC-1) study, which had a complex design.
The effects of adjuvant chemotherapy and chemoradiation in pa-
tients with resected pancreatic cancer were evaluated. The patients
were randomized to (a) observation after surgery, (b) concomitant
chemoradiation alone (40 Gy split course RT with 500 mg/m2 5-FU
iv bolus during the ﬁrst 3 days), (c) chemotherapy alone (leucovorin
20 mg/m2 bolus followed by 5-FU 425 mg/m2 for 5 days, repeated
every 28 days for 6 cycles), (d) chemoradiation followed by 6 cycles
of adjuvant 5-FU/leucovorin treatment. By contrast, for patients
receiving chemoradiotherapy, a negative impact on survival was
observed while a survival advantage for adjuvant chemotherapy
was achieved. This trial was criticized for several reasons as followsits design was considered inappropriate for sequential therapy
analysis, RT details were inadequate (30% of the patients did not
receive RT or treatment differed from planned treatment) and RT
schedule followed a split course.16
Another randomized Radiation Therapy and Oncology Group
(RTOG 97-04) trial evaluated whether gemcitabine (1000 mg/m2/
week) before and after 5-FU based chemoradiation (50.4 Gy/28
fractions) would provide superior outcome to 5-FU (250 mg/m2/
day) before and after 5-FU based chemoradiation. The 3-year
overall survival times (20.5 vs 17 months), and rates (31 vs 22%)
had been indicated for the gemcitabine and 5-FU arms with an
intergroup difference which almost reached statistical signiﬁcance
(p ¼ 0.09).17
After the criticized results of historical randomized trials,
further studies were conducted to see if adjuvant chemoradiation
may be beneﬁcial. Thus, a phase III randomized NCT01013649 trial
is still ongoing in the United States which should be completed by
the year 2020. Nevertheless, the impact of chemoradiation on
overall survival after pancreaticoduodenectomy was evaluated in a
multicenter retrospective study reviewing 955 patients. Median
overall survival times was 40 months for patients treated with
chemoradiation compared with 25 months for those receiving
chemoradiation and 29 months for patients treated only with
adjuvant chemotherapy (p < 0.001). In the population treated with
adjuvant chemoradiation 5-year overall survival was 41% compared
with 26% in patients treated with chemotherapy alone.18
3. Neoadjuvant chemoradiotherapy
The high frequency of disease recurrences and the low survival
rates associated with surgical resection of pancreatic carcinoma
have been usually attributed to residual tumor cells left at the
surgical margins and lymph node involvement. Many institutions
have studied adjuvant therapy to prevent high locoregional and
distant recurrences. However, postoperative adjuvant therapy
could not be performed in 24%e56% of the patients because of
delayed recovery after major surgery, medical comorbidity and
disease progression. Thus, recent researches have focused on pre-
operative neoadjuvant strategies. Sequencing chemoradiation
before surgery may provide theoretical advantages. RT with neo-
adjuvant therapy could be more effective with normal vascular
blood ﬂow, the risk of peritoneal seeding with surgery could be
reduced, response to chemoradiation could be demonstrated
in vivo, unnecessary surgery could be avoided for rapidly progres-
sive biological tumors and metastatic patients that were staged
before surgery.19,20
Fox Chase Cancer Center, evaluated neoadjuvant chemo-
radiation for periampullary tumors. They found a resectability
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fractionated with 4 day infusion of 5-FU and bolus infusion of
mitomycin C on the second day. Median survival was 45 months
in patients who underwent potentially curative resection.21
Eastern Cooperative Oncology Group (ECOG) used a similar
therapeutic regimen with 53 patients, and only 24 of 41 patients
scheduled for surgery were managed with curative resection.
Among these patients median survival was 15.7 months.22 With
the limited efﬁcacy of 5-FU, investigators also evaluated RT used
concurrently with neoadjuvant gemcitabine. Level I data from the
CONKO-001 trial established the role of gemcitabine as an adju-
vant therapy. M.D. Anderson Cancer Center reported results from
a trial which used gemcitabine (400 mg/m2/week) concurrently
with neoadjuvant RT (30 Gy/10 fractions). Seventy-four percent
of 86 patients underwent resection with a 5-year overall survival
rate of 36%.23 Small et al reported a 1-year overall survival rate of
76% for patients with initially resectable pancreatic cancer treated
with full dose gemcitabine (1000 mg/m2) combined with RT
(36 Gy/15 fractions) and reported the tolerability of full dose
gemcitabine with RT.24
Until now, margin-negative pancreatectomy has been the only
known cure for the disease. However, only up to 10%e20% of the
patients have a resectable tumor, and R0 resection rate ranges be-
tween 32, and 71 percent19,25. Positive margins after surgery have
been associated with signiﬁcantly worse survival, similar to that of
the patients with inoperable disease.19 Therefore, much of recent
data on neoadjuvant therapy has focused on borderline resectable
tumors to achieve a higher probability of margin-negative resec-
tion. M.D. Anderson Cancer Center published a series of their pa-
tients with borderline resectable disease treated with neoadjuvant
therapy and reported that 56% of surgical specimens had less than
50% viable tumor cells.26 They found that 41% of the patients had
undergone resection with grossly negative margins and in 94% of
them negative surgical margins were histopathologically
conﬁrmed. Furthermore, median survival time was 40 months for
the patients undergoing resection compared with 13 months for
those not receiving surgery (p < 0.001). Fox Chase Cancer Center
showed similar results. Patients who underwent therapy followed
by surgery had an 85% rate of margin-negative resections.27 These
data suggest that neoadjuvant therapy for borderline resectable
pancreatic cancer may improve the likelihood of an R0 resection,
however randomized trials are needed to test this approach.
4. Chemoradiotherapy for locally advanced unresectable
disease
Approximately 30%e40% of the newly diagnosed pancreatic
carcinoma cases are classiﬁed as locally advanced, non-resectable,
non-metastatic cancers, and those with involvement of major
blood vessels and regional lymph nodes. Currently, concurrent
chemoradiation has been suggested as a standard ﬁrst line treat-
ment option, even though there are still debates on this modality.
GITSG has demonstrated that split course RT amounting to a
total dose of 40e60 Gy with concurrent 5-FU bolus was superior to
RT alone. Median survival timewas 5.5 months for RT alone (60 Gy)
versus 8.3 months for concurrent therapy (40 Gy þ 5-FU) and even
better with dose escalation therapy (11.3 months for 60 Gy þ 5-
FU).28 Subsequently it has been demonstrated that an SMF
regimen (streptozocin, mitomycin C, 5-FU) yielded a signiﬁcantly
inferior survival outcome for patients with unresectable disease
than 5-FU chemoradiation delivered up to 54 Gy followed by SMF
chemotherapy (1-year overall survival 41% vs. 19%, 2-year overall
survival 18% vs 0%).29
Similar to neoadjuvant strategies, with its potent radio-
sensitizing effects, combination of gemcitabine with RT has beensuggested as an ideal treatment for locally advanced pancreatic
carcinoma with efﬁcient locoregional control and substantial sys-
temic effects. A dose of 40 mg/m2 twice weekly in combination
with RT up to a total dose of 50.5 Gy was examined by the Cancer
and Leukemia Group B (CALGB) in a phase II study of 39 patients.
After chemoradiation, patients without disease progression
received gemcitabine alone at weekly doses of 1000 mg/m2 for 5
cycles. Grade 3/4 toxicity identiﬁed in 69% of these patients. The
median survival time was 8.2 months.30 Small et al treated locally
advanced pancreatic carcinoma patients with full dose gemcitabine
concomitantly used with RT (36 Gy/10 fractions, 3 cycles of gem-
citabine). With a median 47% of 1-year overall survival rate, this
study was one of the ﬁrst trials showing the safety of full dose
gemcitabine in combination with RT.24
An ECOG phase III trial attempted to assess the beneﬁt of RT
combined with gemcitabine in the unresectable pancreatic cancer
population, but it was terminated prematurely because of poor
accrual. Although, adding RT to gemcitabine signiﬁcantly improved
survival rates, grade 4 toxicity was also signiﬁcantly higher in the
chemoradiation arm.31
The M.D. Anderson Cancer Center retrospectively examined 114
patients with locally advanced pancreatic carcinoma treated with
combination of RT (30 Gy/10 fractions) with either concurrent 5-FU
(200e300 mg/m2/week) or gemcitabine (250e500 mg/m2/week).
Patients receiving gemcitabine developed signiﬁcantly higher
incidence rates of severe acute toxicity requiring a hospital stay of
more than 5 days with mucosal ulceration with bleeding, Some
patients missed more than 3 doses of gemcitabine and gemcitabine
toxicity also resulted in surgical intervention or death. However, no
statistically signiﬁcant difference was detected between chemo-
therapeutic agents.32
5. RT with targeted therapeutic agents
As a recently popular treatment modality disease-targeted
therapeutic agents have been tested in the treatment of che-
moradiation for pancreatic carcinoma. Promising results were
found especially for epidermal growth factor receptor (EGFR)
agents.
The overexpression of EGFR and gene ampliﬁcation were
detected in 60% of the patients with pancreas carcinoma.33 Erloti-
nib is a reversible tyrosine kinase inhibitor of EGFR.34 Trials eval-
uated erlotinib in combination with chemoradiotherapy in the
treatment of pancreatic carcinoma. Herman et al conducted a phase
II trial for resectable pancreatic cancer patients to demonstrate
progression free (PFS), and overall survival (OS) rates with the use
of erlotinib in combination with chemoradiation and chemo-
therapy. Patients had been treated with erlotinib (100 mg daily)
and capecitabine (800 mg/m2/twice daily) concurrently with in-
tensity modulated radiotherapy (IMRT) (50.4 Gy/28 fractions) after
surgery followed by gemcitabine (1000 mg/m2 on days 1, 8 and 15,
then every 28 days) for 4 cycles. The PFS and OS were 15.6 and 24.4
months, respectively.35 In a phase I trial with erlotinib, gemcitabine
and paclitaxel had been used concurrently with RT for locally
advanced pancreatic cancer, Iannitti et al reported a median sur-
vival of 14 months. Three different dosages of erlotinib had been
tried, and daily dose of 50 mg was found to be more tolerable in
combination with gemcitabine, paclitaxel and RT.36 Duffy et al
showed the results of phase I trial in non-operable pancreas car-
cinoma patients treated with erlotinib (100 mg/daily), gemcitabine
(40 mg/m2/30 min twice weekly) and RT (50.4 Gy/28 fractions over
5.5 weeks). Partial remission (PR) and stable disease rates were 35%
and 53%, respectively.37
Cetuximab is a monoclonal antibody that speciﬁcally binds to
the EGFR. In in vivo and in vitro studies, it has been shown to
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decrease cell proliferation, inhibit regeneration of radiation -
induced defect site and also tumor angiogenesis.38 Fiore et al
applied weekly cetuximab and gemcitabine (300 mg/m2) concur-
rently with RT (50.4 Gy/28 fractions) to 34 patients. They found PR
and SD rates of 24% and 52%, respectively. Median survival was 15.3
months.39 Rembielak et al designed a phase II trial with cetuximab
(ﬁrst dose of 400 mg/m2 followed by 250 mg/m2 weekly) and RT
(50.4 Gy/28 fractions). They reported that the treatment had been
well tolerated and most patients (71%) had experienced acute
toxicities of grade 1 or 2. Six months after the treatment only 33% of
them had been free from metastatic progression. Median overall
survival was 7.5 months (1 year 33% and 3 year 11%).40
Panitumumab is a EGFR-related monoclonal antibody. A phase I
trial was designed for evaluating addition of panitumumab to
gemcitabine based chemoradiotherapy in patients with locally
advanced pancreatic cancer. Fourteen patients were treated with
panitumumab (1e2.5 mg/kg/weekly for 6 weeks) combined with
gemcitabine (300 mg/m2/weekly for 6 weeks) and RT (50.4 Gy/28
fractions) followed by gemcitabine 1000 mg/m2 until progression.
Maximum tolerable panitumumab dose was 1.5 mg/kg. Grade 3
toxicities during treatment were neutropenia (33%), fatigue (17%),
nausea and vomiting (17%). PFS was 8.9 months.41
Bevacizumab is a monoclonal antibody related to vascular
endothelial growth factor (VEGF). Studies evaluated bevacizumab
with chemoradiation for pancreas carcinoma. Van Buren et al
tested the efﬁcacy of bevacizumab with RT in a phase II trial for
resectable pancreatic carcinoma. Fifty-nine patients had been
treated with gemcitabine (1500 mg/m2) plus bevacizumab (10 mg/
m2) every 2 weeks for 3 cycles followed by RT (30Gy/10 fractions)
and bevacizumab. Pancreatic resections were performed in 73% of
the patients and margin-negative outcomes were observed in 88%
of those patients. Median overall survival times before, and after
the resection had been 16.8, and 19.7 months, respectively while
corresponding median PFS times had been 6.6 months, and 12.9
months, respectively.42 Small et al conducted a phase II trìal for
patents wìth localised pancreatic carcinoma in that patients had
received gemcitabine 1000 mg/m2 (day 1 and 8, 7 doses) and
bevacizumab 10mg/kg (every 2week, 5 doses) in combinationwith
RT (36 Gy). Patients with resectable tumors had undergone surgery
6e8 weeks after the last dose of bevacizumab. Maintenance doses
of gemcitabine and bevacizumab had been delivered to patients
who had unresected tumors without disease progression. Median
PFS and OS times had been 9.9 and 11.8 months, respectively.43
6. Conclusion
Pancreatic carcinoma is a malignancy with poor prognosis. Pa-
tients are diagnosed at an advanced stage of the disease therefore,
multidisciplinary approach is needed. Improved survival beneﬁt
and R0 resection possibility have been shownwith chemoradiation
for locally advanced and borderline resectable disease. The effec-
tiveness of 5-FU and gemcitabine has been demonstrated on che-
moradiation for locally advanced and borderline resectable disease.
RT used in combination with EGFR and VEGF activity inhibiting
agents are also promising.
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